Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GRK2 | P25098 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018932 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBMAPTPKMALDH1A1 | |
| SCHEMBL23417745 | 0.85 | POLB (0.51) | POLBMAPTPKMALDH1A1GAA | |
| SCHEMBL3078183 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBMAPTPKMALDH1A1 | |
| SCHEMBL18997647 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2POLBMAPTPKMALDH1A1 | |
| SCHEMBL23222224 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2POLBMAPTPKMALDH1A1 | |
| SCHEMBL21900756 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBMAPTPKMALDH1A1 | |
| SCHEMBL19049554 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBMAPTPKMALDH1A1 | |
| SCHEMBL28135499 | 0.81 | MAPK1 (0.50) | SMN1; SMN2POLBPKMALDH1A1GAA | |
| SCHEMBL15480425 | 0.80 | HDAC1 (0.63) | SMN1; SMN2POLBPKMALDH1A1GRK2 | |
| SCHEMBL2190433 | 0.79 | POLB (0.59) | SMN1; SMN2POLBMAPTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | SMN1; SMN2 4331/4885POLB 1589/4885MAPT 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.